Menu

Blog

Page 2926

Dec 15, 2022

Aaron Cravens at Rejuvenation Startup Summit 2022

Posted by in categories: biotech/medical, life extension

New video: Dr. Aaron Cravens, CEO of Revel Pharmaceuticals at #RejuvenationStartupSummit 2022 about developing designer enzymes to treat diseases of aging, e.g. glucosepane crosslink breakers to prevent hardening of tissues such as muscle, skin, and arteries leading to increased blood pressure, vascular damage, and wrinkling of the skin.

Enjoy →

Continue reading “Aaron Cravens at Rejuvenation Startup Summit 2022” »

Dec 15, 2022

Skin bioprinting: the future of burn wound reconstruction?

Posted by in categories: 3D printing, bioengineering, bioprinting, biotech/medical, robotics/AI

In addition to laser-assisted bioprinting, other light-based 3D bioprinting techniques include digital light processing (DLP) and two-photon polymerization (TPP)-based 3D bioprinting. DLP uses a digital micro-mirror device to project a patterned mask of ultraviolet (UV)/visible range light onto a polymer solution, which in turn results in photopolymerization of the polymer in contact [56, 57]. DLP can achieve high resolution with rapid printing speed regardless of the layer’s complexity and area. In this method of 3D bioprinting, the dynamics of the polymerization can be regulated by modulating the power of the light source, the printing rate, and the type and concentrations of the photoinitiators used. TPP, on the other hand, utilizes a focused near-infrared femtosecond laser of wavelength 800 nm to induce polymerization of the monomer solution [56]. TPP can provide a very high resolution beyond the light diffraction limit since two-photon absorption only happens in the center region of the laser focal spot where the energy is above the threshold to trigger two-photon absorption [56].

The recent development of the integrated tissue and organ printer (ITOP) by our group allows for bioprinting of human scale tissues of any shape [45]. The ITOP facilitates bioprinting with very high precision; it has a resolution of 50 μm for cells and 2 μm for scaffolding materials. This enables recapitulation of heterocellular tissue biology and allows for fabrication of functional tissues. The ITOP is configured to deliver the bioink within a stronger water-soluble gel, Pluronic F-127, that helps the printed cells to maintain their shape during the printing process. Thereafter, the Pluronic F-127 scaffolding is simply washed away from the bioprinted tissue. To ensure adequate oxygen diffusion into the bioprinted tissue, microchannels are created with the biodegradable polymer, polycaprolactone (PCL). Stable human-scale ear cartilage, bone, and skeletal muscle structures were printed with the ITOP, which when implanted in animal models, matured into functional tissue and developed a network of blood vessels and nerves [45]. In addition to the use of materials such as Pluronic F-127 and PCL for support scaffolds, other strategies for improving structural integrity of the 3D bioprinted constructs include the use of suitable thickening agents such as hydroxyapatite particles, nanocellulose, and Xanthan and gellan gum. Further, the use of hydrogel mixtures instead of a single hydrogel is a helpful strategy. For example, the use of gelatin-methacrylamide (GelMA)/hyaluronic acid (HA) mixture instead of GelMA alone shows enhanced printability since HA improves the viscosity of mixture while crosslinking of GelMA retains post-printing structural integrity [58].

To date, several studies have investigated skin bioprinting as a novel approach to reconstruct functional skin tissue [44, 59,60,61,62,63,64,65,66,67]. Some of the advantages of fabrication of skin constructs using bioprinting compared to other conventional tissue engineering strategies are the automation and standardization for clinical application and precision in deposition of cells. Although conventional tissue engineering strategies (i.e., culturing cells on a scaffold and maturation in a bioreactor) might currently achieve similar results to bioprinting, there are still many aspects that require improvements in the production process of the skin, including the long production times to obtain large surfaces required to cover the entire burn wounds [67]. There are two different approaches to skin bioprinting: in situ bioprinting and in vitro bioprinting. Both these approaches are similar except for the site of printing and tissue maturation. In situ bioprinting involves direct printing of pre-cultured cells onto the site of injury for wound closure allowing for skin maturation at the wound site. The use of in situ bioprinting for burn wound reconstruction provides several advantages, including precise deposition of cells on the wound, elimination of the need for expensive and time-consuming in vitro differentiation, and the need for multiple surgeries [68]. In the case of in vitro bioprinting, printing is done in vitro and the bioprinted skin is allowed to mature in a bioreactor, after which it is transplanted to the wound site. Our group is working on developing approaches for in situ bioprinting [69]. An inkjet-based bioprinting system was developed to print primary human keratinocytes and fibroblasts on dorsal full-thickness (3 cm × 2.5 cm) wounds in athymic nude mice. First, fibroblasts (1.0 × 105 cells/cm2) incorporated into fibrinogen/collagen hydrogels were printed on the wounds, followed by a layer of keratinocytes (1.0 × 107 cells/cm2) above the fibroblast layer [69]. Complete re-epithelialization was achieved in these relatively large wounds after 8 weeks. This bioprinting system involves the use of a novel cartridge-based delivery system for deposition of cells at the site of injury. A laser scanner scans the wound and creates a map of the missing skin, and fibroblasts and keratinocytes are printed directly on to this area. These cells then form the dermis and epidermis, respectively. This was further validated in a pig wound model, wherein larger wounds (10 cm × 10 cm) were treated by printing a layer of fibroblasts followed by keratinocytes (10 million cells each) [69]. Wound healing and complete re-epithelialization were observed by 8 weeks. This pivotal work shows the potential of using in situ bioprinting approaches for wound healing and skin regeneration. Clinical studies are currently in progress with this in situ bioprinting system. In another study, amniotic fluid-derived stem cells (AFSCs) were bioprinted directly onto full-thickness dorsal skin wounds (2 cm × 2 cm) of nu/nu mice using a pressure-driven, computer-controlled bioprinting device [44]. AFSCs and bone marrow-derived mesenchymal stem cells were suspended in fibrin-collagen gel, mixed with thrombin solution (a crosslinking agent), and then printed onto the wound site. Two layers of fibrin-collagen gel and thrombin were printed on the wounds. Bioprinting enabled effective wound closure and re-epithelialization likely through a growth factor-mediated mechanism by the stem cells. These studies indicate the potential of using in situ bioprinting for treatment of large wounds and burns.

Dec 15, 2022

Cornellian-founded company implants 3D-bioprinted ear

Posted by in categories: bioengineering, biotech/medical, education

In a first-of-its-kind clinical trial, a human has received a 3D-bioprinted ear implant grown from the patient’s own living cells – thanks to a technology platform developed by a Cornellian-founded startup company.

This bioengineered breakthrough has the potential to significantly improve the lives of the approximately 1,500 children who are born annually in the U.S. with microtia, a congenital ear deformity. The approach could eventually lead to tissue implants for treating other conditions and traumatic injuries, reconstructive and regenerative therapy, and possibly even the biomanufacture of whole organs.

The company, 3DBio Therapeutics, was founded in 2014 by Dan Cohen ‘04, M.S. ‘07, Ph.D. ‘10, along with Lawrence Bonassar, the Daljit S. and Elaine Sarkaria Professor in Biomedical Engineering and in Mechanical and Aerospace Engineering in the College of Engineering, and Hod Lipson, who taught at Cornell for 14 years and is now a professor at Columbia University.

Dec 15, 2022

A.I. Is Not Sentient. Why Do People Say It Is?

Posted by in category: robotics/AI

Robots can’t think or feel, despite what the researchers who build them want to believe.

Dec 15, 2022

Honda says VR is changing how it designs cars. You might not notice

Posted by in categories: biotech/medical, virtual reality

Honda is pulling away from a design practice that’s (literally) shaped auto making since the ’30s.

The $43 billion company still depends on life-size clay models to evaluate its designs, a tried and true method pioneered by GM designer Harley Earl. But Honda is gradually relying less on the practice, ever since the Coronavirus tore across the globe and resulting lockdowns divided its teams in Los Angeles, Ohio and Japan. The way Honda tells it, those early 2020 travel rules “threatened” its designers’ ability to work with engineers on the ’24 Prologue, creating a window for a deeper dive into virtual reality.

Dec 15, 2022

Tesla investors grow restless as Elon Musk’s focus stays on Twitter

Posted by in categories: Elon Musk, sustainability, transportation

Top Tesla investors are growing frustrated with billionaire Elon Musk’s focus on Twitter as the electric car company’s stock prices continue to fall this month.

Dec 14, 2022

Coronavirus Cure Breakthrough — Scientists Have Found a Potential Basis

Posted by in categories: biotech/medical, innovation

Researchers have discovered that salen can effectively bind a number of proteins of the coronavirus SARS-CoV-2.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the official name of the virus strain that causes coronavirus disease (COVID-19). Previous to this name being adopted, it was commonly referred to as the 2019 novel coronavirus (2019-nCoV), the Wuhan coronavirus, or the Wuhan virus.

Dec 14, 2022

China’s launch of world’s 1st methane-fueled orbital rocket fails, 14 satellites lost

Posted by in category: satellites

A rocket developed by Chinese private space launch provider Landspace failed to reach orbit on Wednesday (Dec. 14), losing 14 satellites in the process.

Dec 14, 2022

Human-like reasoning for an AI

Posted by in categories: robotics/AI, space

In June 2022, Amazon re: MARS, the company’s in-person event that explores advancements and practical applications within machine learning, automation, robotics, and space (MARS), took place in Las Vegas. The event brought together thought leaders and technical experts building the future of artificial intelligence and machine learning, and included keynote talks, innovation spotlights, and a series of breakout-session talks.

Now, in our re: MARS revisited series, Amazon Science is taking a look back at some of the keynotes, and breakout session talks from the conference. We’ve asked presenters three questions about their talks, and provide the full video of their presentation.

Continue reading “Human-like reasoning for an AI” »

Dec 14, 2022

After banning the college student who tracked Elon Musk’s jet, Twitter also banned sharing links to his jet tracker accounts on other social media platforms

Posted by in categories: Elon Musk, policy

What is the point of all that wealth if you don’t get to be petty?


Twitter blocked links to Jack Sweeney’s Instagram and Facebook accounts tracking Elon Musk’s jet and announced an updated privacy policy.